Actual possibilities and perspectives of biological drugs in treatment of systemic vasculitides. III. Biological drugs in giant cell arteritis
PDF EN/BG

Keywords

giant cell arteritis, treatment, biological drugs, TNF-alpha-inhibitors, tocilizumab

How to Cite

[1]
Dimov, D. 2021. Actual possibilities and perspectives of biological drugs in treatment of systemic vasculitides. III. Biological drugs in giant cell arteritis. Rheumatology (Bulgaria). 29, 1 (Mar. 2021), 8-20. DOI:https://doi.org/10.35465/29.1.2020.pp8-20.

Abstract

A review of the literary data about the hitherto exiting investigations on biological drugs (BDs) as an alternative of the corticosteroids (CSs) – the current basal therapy of giant cell arteritis (GCA) is presented. The TNF-alpha-inhibitors are already definitely discarded on the account of their inefficiency and inadequate tolerability. The favorable initial results of BDs against IL-1, CTLA4-iGg1 and especially IL-12/23 should receive a reliable assessment after completion of the additional large-scale investigations. Indisputably only the data on efficacy of tocilizumab (anti-IL-6) for induction and maintenance of GCA remission and its marked CS-saving effect are convincing. Reasonably, TCM received a permission for use as adjunctive therapy in the management of GCA.
https://doi.org/10.35465/29.1.2020.pp8-20
PDF EN/BG
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.